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Sleep disturbance is considered as an important symptom of acute and protracted opiate withdrawal. Current results suggest that
sleep disturbance maybe takenasa predictor of relapse. Appropriate sleep enhancement therapy will be in favorof the retention in
treatment for opiate addicts. Our previous studies have shown that electroacupuncture (EA) is eﬀective in suppressing morphine
withdrawal syndrome. The aim of the present study is to investigate the eﬀect of 2 and 100Hz EA on the sleep disturbance
during morphine withdrawal. Rats were made dependent on morphine by repeated morphine injections (escalating doses of 5–
80mgkg−1, subcutaneously, twice a day) for 5 days. EA of 2 or 100Hz was given twice a day for 3 days, starting at 48h after
the last morphine injection. Electroencephalogram and electromyogram were monitored at the end of the ﬁrst and the last EA
treatments, respectively. Results showed that non-rapid eye movement (NREM) sleep, REM sleep and total sleep time decreased
dramatically, while the sleep latency prolonged signiﬁcantly during acute morphine withdrawal. Both 2 and 100Hz EA produced
a signiﬁcant increase in NREM sleep, REM sleep and total sleep time. It was suggested that EA could be a potential treatment for
sleep disturbance during morphine withdrawal.
1.Introduction
Sleep disturbance is a signiﬁcant feature of acute and pro-
tracted withdrawal syndrome during detoxiﬁcation from
opiates. Howe et al. [1, 2] reported that heroin-dependent
patients showed a marked increase in waking and decrease in
bothslow waveand rapideyemovement(REM)sleepduring
acute heroin withdrawal. The patients’ total sleep time was
dramatically suppressed on Days 2 and 3 of withdrawal, and
remained below normal control values on Days 5–7.
Methadone, as a long-acting opioid-agonist, is widely
used as a substitution of heroin for the treatment of with-
drawal syndrome and prevention of relapse in heroin-de-
pendent patients. However, the opiate addicts often com-
plain of sleep diﬃculties during methadone maintenance
treatment (MMT). Some of them, in fact, attribute their
premature exit from this therapy to sleep diﬃculties [3–5].
Indeed, the persistent insomnia in drug-dependency may
provoke heroin relapse during methadone maintenance [6].
Our previous clinical studies have demonstrated that
transcutaneouselectricalacupointstimulation(TEAS)could
ameliorate heroin abstinence syndrome and postpone re-
lapse in heroin addicts [7, 8]. In fact, TEAS was reported
to show an immediate hypnotic eﬀect during the treatment
in one-third of the patients [9]. It seemed rational to
further study the eﬀect of electroacupuncture (EA) on sleep
enhancement with measurement of electroencephalogram
(EEG) and electromyogram (EMG) in animal model ofmor-
phine withdrawal.
The purpose of this study was to characterize the sleep
proﬁle of morphine withdrawal rats with EEG and EMG,
and to evaluate whether 2 and 100Hz EA can improve sleep
disturbance during morphine withdrawal.
2.Methods
2.1. Animals. The animals used were male Sprague-Dawley
rats (Grade 1, purchased from Animal Center of Peking
University, Beijing), weighing 220–250g each. Each rat was
housed individually in a thermoregulated room (22–24◦C)
with a 12:12h light-dark cycle, and had access to food2 Evidence-Based Complementary and Alternative Medicine
and water ad libitum. All experimental procedures were
approvedby theAnimal UseCommittee ofPeking University
HealthScienceCenterandcarefullydesignedtominimize the
number of animals used and their suﬀering.
2.2. Fixation of Electrodes. Sterile surgery was performed
under general anesthesia induced by sodium pentobarbital
(40–50mgkg−1, intraperitoneally). The rats were placed in
a Kopf stereotaxic instrument with blunt ear bars. Two stain-
less-steelscrewsattachedtoinsulatedwirewereimplantedon
the skull over the frontal-parietal cortex to record the EEG.
Two electrodes were placed 2mm anterior and 5 mm lateral
to the bregma. Two insulated stainless-steel wires bared at
the tips were sutured onto the dorsal cervical neck muscles
to record the EMG. All of these electrodes were attached to
a miniature connector. The implant assembly was aﬃxed to
the skull with dental acrylic [10]. All animals were allowed 7
days for recovery before the onset of experiments.
2.3. Recording Procedures and Computerized Analysis of EEG
and EMG Signals. For electrophysiological recording, a
lightweight shielded cable which was attached to a counter-
balanced swivel permitting free movement was connected
to the plug on the rat’s head. All rats were studied in
their home-cages in a noise-attenuated environment, free
from any interruption. Cortical EEG and EMG signals were
ampliﬁed and ﬁltered (EEG, 0.5–30Hz; EMG, 20–200Hz),
then digitized at a sampling rate of 200Hz and recorded
by biopac MP 150 system (Santa Barbara, CA, USA).
After that, polygraphic recordings were automatically scored
oﬄine by 4-s epochs as wakefulness, non-REM (NREM)
sleep and REM sleep by SleepSign software (Kissei Comtec,
Nagano, Japan). Initially, an expert observer selected the
characteristic samples from the three stages of vigilance
(wake, NREM and REM sleep) in each day recording of
each rat, according to previously validated criteria [10–12]
as follows: (i) wakefulness was identiﬁed by low-amplitude,
fast EEG activity (mainly in α (8–13Hz) and β (13–30Hz)
band)andhighEMG activity;(ii)NREMsleepwas identiﬁed
by high-amplitude, slow EEG activity (delta activity, 0.5–
4Hz, was increased to dominate the power spectra) and low
EMG activity relative to that of waking. NREM sleep was
considered initiated if six consecutive 4-s epochs (24s) were
scored as NREM sleep; (iii) REM sleep was identiﬁed by
the presence of low-amplitude and regular theta activity (4–
8Hz) on EEG, together with very low EMG activity (shown
in Figure 1). The criteria of the auto-scoring could then
be conﬁgured and saved in SleepSign software according
to these reference samples. As a ﬁnal step, deﬁned sleep-
wake architectures were examined visually and corrected if
necessary.
2.4. Drugs and Drug Administration. The rats were injected
subcutaneously with morphine hydrochloride in normal
saline twice a day (at 8:00 and 20:00h) at the following doses
per injection: 5mgkg−1 on the ﬁrst day, followed by 10, 20,
40, 80mgkg−1, respectively. The ﬁrst injection (5mgkg−1)
was on the night of Day 2 (shown in Figure 2), while the last
injection (80mgkg−1)w a sg i v e no nt h em o r n i n go fD a y7 .
The injection volume was 2mlkg−1.
2.5. EA. Rats were kept in specially designed holders, with
their hind legs and tails exposed. Two stainless-steel needles
of 0.25mm diameter and 5mm in length were inserted
into two sites on the hind legs: one is the “Zusanli” point
(ST36) near the knee joint (5mm lateral to the anterior
tubercle of tibia) and the other is the “Sanyinjiao” point
(SP6) near ankle joint (at the level of the superior border
of the medial melleolus, between the posterior border of the
tibia and the anterior border of the Achilles tendon). Con-
stant current square-wave electrical stimulation produced
by a programmed pulse generator HANS LH-800 (Beijing
Astronautics and Aeronautics Aviation University, Beijing,
C h i n a )w a sg i v e nf o rat o t a lo f3 0m i n .T h ef r e q u e n c yo f
stimulation used was 2Hz (0.6ms pulse width) or 100Hz
(0.2ms pulse width). The intensity of the stimulation was
increased stepwise from 0.5 to 1mA, and ended at 1.5mA,
with each step lasting for 10min.
2.6. Experimental Procedures. As shown in Figure 2,a f t e r7 -
day recovery from surgery, all rats received 2-day recording
of the EEG and EMG, starting at 9:00AM and lasting for
6h per day (baseline recordings 1 and 2), the mean values of
NREM, REMand total sleep time were served as baseline. All
rats were then administered subcutaneously with escalating
dose of morphine hydrochloride. Twenty-four hours after
the last injection of morphine, sleep-wakefulness state was
monitored for 6h (recording 3) to assess the eﬀect of
morphine withdrawal on the sleep state.
Forty-eight hours after the last injection of morphine,
rats were randomly divided into three groups of ﬁve each.
Group 1 received no treatment serving as blank control
g r o u p ,g r o u p s2a n d3w e r eg i v e n2a n d1 0 0H zE A ,r e s p e c -
tively twice aday for3 days. After theﬁrst EA treatment (Day
9morning, 30minafter theﬁrst EAtreatment) and 3-dayEA
treatment (Day 12 morning), all rats received two recordings
of the EEG and EMG (recordings 4 and 5) to observe the
eﬀect of single or multiple EA treatment on sleep state in
morphine withdrawal rats.
2.7. Data Analysis. Data were processed using commercially
availablesoftwareGraphPad PRISM4.0.Datawerepresented
as mean ± standard error of the mean (SEM) and analyzed
with two-way ANOVA followed by Bonferroni post-test.
Moreover, two-tailed paired t-test was used where appropri-
ate, with each animal serving as its own control. Statistical
signiﬁcance was set at P<. 05.
3.Results
3.1. Acute Withdrawal from Chronic Morphine Treatment
Caused Sleep Disturbance. Comparison of classical sleep
parameters (shown in Figure 3 and Table 1, sleep latency;
REM sleep; NREM sleep; total sleep time) between base-
line days (recordings 1 and 2) and acute withdrawal day
(recording 3, starting at 24h after last morphine injection)Evidence-Based Complementary and Alternative Medicine 3
Wake NREM sleep REM sleep
EEG
EMG
50μV
50μV
5s
Figure 1: Typical samples of EEG and EMG classiﬁed as wake, NREM sleep and REM sleep.
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Figure 2: Schematic diagram for experimental design.
Table 1:Changesofsleeptimeandsleeplatencyinminutes inacute
morphine withdrawal rats.
Baseline (B) Withdrawal (W) W/B
(%)
P-value
NREM sleep 145.6 ± 12.93 76.34 ± 11.74 52.43 .0001
REM sleep 5.284 ± 1.192 1.610 ± 0.5483 30.47 .0030
Total sleep
time
150.9 ± 13.25 77.95 ± 11.98 51.66 .0001
Sleep latency 22.59 ± 3.759 29.31 ± 4.305 129.75 .0260
All the values in this table are min ± SEM.
by two-tailed paired t-test revealed a signiﬁcant decrease in
NREMsleep(47.57%reduction),REMsleep (69.53%reduc-
tion) and total sleep time (48.34% reduction). Meanwhile,
the sleep latency was signiﬁcantly longer (29.75% increase)
during acute withdrawal.
3.2. Single 100Hz EA was Better than 2Hz on Increasing Sleep
Time in Morphine Withdrawal Rats. After recording of the
sleep state on the ﬁrst withdrawal day, rats were randomly
divided into three groups of ﬁve each. EA of 2 or 100Hz was
given for 3 days twice a day from 48h after last morphine
injection (Day 9). Rats of the control group were staying in
home-cage. In order to investigate the eﬀect of single EA
treatment on sleep disturbance, EEG and EMG of all three
groupswere monitored for6h (recording 4)atthe endofthe
ﬁrst EA treatment. Results were deﬁned as percent diﬀerence
of sleep time between the experiment day and the baseline
day over baseline (% (sleep time in experiment day—sleep
time in baseline day)/baseline).
Figure 4(a) illustrates that single EA treatment (2 or
100Hz) produced no signiﬁcant change of the sleep latency.
Two-way ANOVA indicated no signiﬁcant interaction
between treatment and time (F2,24 = 1.49; P = .2465), nor
any signiﬁcant diﬀerence between pre- and post-treatment
(F1,24 = 0.04; P = .8384) and among the groups of animals
that received diﬀerent treatments (no EA, 2 or 100Hz EA)
(F2,24 = 1.75; P = .1954).
However, single session of EA did improve the sleep
proﬁle depicted by sleep time.
Figure 4(b) shows the eﬀect of single EA treatment on
REM sleep. Two-way ANOVA indicated signiﬁcant diﬀer-
ence between pre- and post-treatment (F1,24 = 5.45; P =
.0282). Single 100Hz EA signiﬁcantly increased the REM
sleep (compared with control group and pre-treatment by
Bonferroni post-test).
Figure 4(c) shows the eﬀect of single EA treatment on
NREMsleep.Two-way ANOVAfortreatment ×time showed
signiﬁcant eﬀects for treatment (F2,24 = 12.46; P = .0002)
and time (F1,24 = 6.02; P = .0218), with no interaction (F2,24
= 1.56; P = .2310). After the single session of either 2 or
100Hz EA, time spent in NREM sleep was raised apparently
(100Hz group: compared with control group and pre-
treatment by Bonferroni post-test; 2Hz group: compared
with pre-treatment by paired t-test). The 100Hz group
showed better eﬀect than 2Hz (compared with data after
2Hz EA by Bonferroni post-test).
Figure 4(d) shows that either 2 or 100Hz EA increased
the total sleep time (100Hz group: compared with control
group and pre-treatment by Bonferroni post-test; 2Hz
group: compared with pre-treatment by paired t-test). Two-
way ANOVA indicated signiﬁcant eﬀects for treatment
(F2,24 = 12.98; P = .0002) and time (F1,24 = 7.74; P = .0103),4 Evidence-Based Complementary and Alternative Medicine
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Figure 3: Sleep latency, time spent in NREM, REM sleep and total sleep time during 6-h recording in baseline and acute withdrawal days.
Emptyandﬁlledcolumnsshowthedatainbaselinedayandacutewithdrawalday(startingat24hafterlastmorphineinjection),respectively.
∗P<. 05; ∗∗P<. 01; ∗∗∗P<. 001 compared with baseline by paired t-test; n = 15.
with no interaction (F2,24 = 2.11; P = .1426). The eﬀect of
100Hz EA was better than 2Hz (compared with data after
2Hz by Bonferroni post-test).
3.3. Multiple Application of 2 or 100Hz EA was Both Eﬀective
in Normalizing Sleep Time in Morphine Withdrawal Rats.
When 3-day EA treatment was ﬁnished on the night of Day
11, all rats received another recording of EEG and EMG (on
Day 12 morning, recording 5) to assess the eﬀect of multiple
application of EA on sleep disturbance.
After 5-day withdrawal from chronic morphine injec-
tion, the REM sleep, NREM sleep and total sleep time were
still below the baseline values in the control group, with
longer sleep latency (Figure 5).
Figure 5(a) shows that for sleep latency, no statistical
diﬀerence was found among all the groups.
Figure 5(b) displays that multiple application of either 2
or 100Hz EA markedly increased REM sleep compared with
pretreatment level. There was a signiﬁcant eﬀect for time
(F1,24 = 6.68; P = .0163).
Figure 5(c) shows the eﬀect of multiple EA treatment on
NREMsleep.Two-way ANOVAfortreatment ×time showed
signiﬁcant eﬀects for treatment (F2,24 = 9.13; P = .0011) and
time (F1,24 = 9.59; P = .0049), with no interaction (F2,24 =
2.42; P = .1102).
Figure 5(d) shows the eﬀect of multiple EA treatment
on total sleep time. Two-way ANOVA indicated signiﬁcant
eﬀects for treatment (F2,24 = 6.38; P = .0080) and time
(F1,24 = 17.36; P = .0003), with no interaction (F2,24 = 1.2;
P = .3186).
Post hoc analysis showed thataftermultipleapplicationof
either2or100HzEA,REM,NREMsleepandtotalsleeptime
were obviously increased (compared with control group and
pre-treatment level by Bonferroni post-test. REM sleep after
100Hz treatment was compared with pre-treatment level by
paired t-test).Evidence-Based Complementary and Alternative Medicine 5
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Figure 4: Eﬀect of single EA treatment on sleep latency (a), time spent in NREM (c), REM sleep (b) and total sleep time (d) during 6-h
recording after morphine withdrawal. Empty columns show the data during acute morphine withdrawal before various treatments, and
ﬁlled columns after the treatment (single session of 2Hz, 100Hz or without EA in control group). ∗P<. 05 compared with the data before
treatment; #P<. 05, ###P<. 001 compared with data after treatment in control group. !P<. 05 compared with the data after treatment in
2Hzgroup.n = 5.
4.Discussion
During acute abstinence, there was a dramatic decrease of
REM,NREMsleep andtotalsleeptime, with prolongedsleep
latency in morphine withdrawal rats. The sleep disturbance
remained for at least 5 days after the last morphine injection.
This was similar to reports in opiate addicts and ﬁndings of
other investigators who used diﬀerent procedure to produce
morphine dependence [1, 2, 13]. Therefore, the animal
model adopted here appeared to be suitable for studying
sleep impairment during morphine withdrawal.
The mechanism of the sleep disturbance during with-
drawal remains unclear.
Wake-sleep regulatory system includes the arousal-cir-
cuitry which promotes wakefulness and the sleep-producing
circuitry.Mutualinhibitionbetweenthesetwoneuralcircuits
results in switching properties that deﬁne discrete wake and
sleep states [14].
One important branch of the ascending arousal sys-
tem originates from monoaminergic neurons in the upper
brainstem and caudal hypothalamus, including the locus
coeruleus (LC), dorsal and median raphe nuclei, ventral
periaqueductal gray matter and tuberomammillary neurons.
Their projections activate neurons throughout the cerebral
cortex. In addition, the inputto cerebral cortex is augmented
by lateral hypothalamic peptidergic neurons and basal fore-
brain neurons. Firing of the monoaminergic neurons usually
increase during wakefulness, slow down during NREM sleep
and stop altogether during REM sleep [14].
Opioid receptors have been found in the brain regions
thatareinvolvedin sleepregulation andithasbeensuggested
that endogenous opioids play a role in the induction and
maintenance of sleep state [12, 15–17].
Enkephalin containing neurons are widely distributed
in the brain region related to sleep regulation such as the
solitary tract nucleus, the preoptic area and the raphe.
Enkephalinergic ﬁbers projecting to the noradrenergic LC
neurons exert an inhibitory eﬀect on the activity of post-
synaptic neurons by locally delivered opioids, and result in
decreased wakefulness and increased slow wave sleep [17].
Dynorphin inhibits noradrenergic LC neurons by sup-
pressing excitatory inputs via presynaptic kappa-receptors
[18].6 Evidence-Based Complementary and Alternative Medicine
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Figure 5: Eﬀect of 3-day EA treatment on sleep latency (a), time spent in NREM (c), REM sleep (b) and total sleep time (d) during 6-h
recording after morphinewithdrawal.Empty columnsshowthedata duringacute morphinewithdrawalbefore varioustreatments andﬁlled
columns after the treatment (3-day EA treatment of 2Hz, 100Hz or without EA in the control group). ∗P<. 05 compared with the data
before treatment; #P<. 05, ##P<. 01, ###P<. 001 compared with data after treatment in control group. n = 5.
Exogenous opioids such as morphine bind to the same
site as the endogenous opioids and suppress the production
of endogenous opioids, thereby reduce their control on sleep
[17]. When the morphine exposure is stopped abruptly,
the functions of endogenous opioids are still below the
normal level [19, 20], which may cause a rebound of the
function of LC or other wake-sleep regulatory system in
morphine withdrawal rats. Indeed, evidence obtained from
electrophysiological studies revealed the hyperactivity of
LC during morphine withdrawal [15, 21], which will lead
to an elevated release of noradrenaline [22, 23]. In this
regard, one could expect that the sleep disturbance during
morphine withdrawal is due, at least in part, to the decreased
endogenous opioids level and the resultant disinhibition of
noradrenergic neurons in the LC.
In addition to distorted noradrenergic neurotransmis-
sion, changes in glutamatergic, GABAergic, serotonergic and
cholinergic systems during morphine withdrawal [24–31]
have also been shown to play important roles in sleep home-
ostasis [32].
It is worth noting that the neuropeptideorexin in the lat-
eral hypothalamus is reported to play a role in manipulat-
ing sleep-waking cycle and responses to morphine [33–35].
Morphine withdrawal produces acute activation of orexin
cells accompanied by an increase of orexin gene expression.
On the contrary, orexin knock-out mice display attenuated
morphine withdrawal syndrome [33, 34].
In the present study, we found that single session of
EA alleviated the sleep disorder in morphine withdrawal
rats, with 100Hz more eﬀective than 2Hz. After 3-day EA
treatment, all three parameters of sleep time (REM, NREM
and total sleep time) returned to baseline level. In this case,
2Hz was as eﬀective as 100Hz.
Our previous works showed that 2Hz EA produced a
signiﬁcant increase in the content of enkephalin and β-
endorphin, while 100Hz increased that of dynorphin in
central nervous system [36]. We also reported that 100Hz
EA increased the spinal dynorphin release in morphine-
dependent rats after withdrawal, an eﬀect readily reversed
by intrathecal injection of dynorphin antiserum or kappa
opioid antagonist nor-BNI. These results suggested that
dynorphin and kappa opioid receptors might be responsible
for ameliorating withdrawal syndrome [20].
We presumed that the facilitated release of endogenous
opioids by 2 and 100Hz EA probably compensated the
deﬁciency of the endogenous opioids during morphineEvidence-Based Complementary and Alternative Medicine 7
withdrawal, thereby inhibited the hyperactivity of LC neu-
rons and restored the sleep-wake homeostasis.
Dynorphin may also participate in the sleep regulation
by exerting inﬂuences on sleep-promoting neurons. It is well
knownthatthereisapopulationofsleep-promotingneurons
in the ventrolateral preoptic nucleus (VLPO), which is con-
nectedwithascendingarousalsystemmentionedearlier[37].
Lesion of VLPO by ibotenic acid resulted in loss of NREM
and REM sleep [38]. Recent study demonstrated that kappa
opioidreceptors were expressed inVLPO neurons,and direct
infusion of dynorphin A into VLPO increased NREM sleep
[12]. Therefore, VLPO might be another important brain
target where 100Hz EA-accelerated release of dynorphin
plays a role in improving the insomnia during abstinence.
Earlier works ofGuo et al. [39–41]r e p o r t e dt h a t2H zE A
increased preproenkephalin (PPE) mRNA level, whereas 100
Hz EA increased preprodynorphin (PPD) mRNA level in
brain, which might account for the cumulative therapeutic
eﬀect on sleep disturbance with 3-day EA treatment.
More information is needed to fully understand the
mechanisms underlying sleep disturbance during morphine
withdrawal and its modulation by EA.
Opiate dependence is characterized by a high incidence
of relapse following detoxiﬁcation [42]. Sleep disturbance
is positively correlated with increased potential of relapse
to heroin abuse. Individuals with shorter sleep time seem
more likely to leave treatment earlier [43]. If the problem
of sleep disturbance is resolved, the risk of relapse may be
reduced. Therefore, the improvement of sleep proﬁle during
morphine withdrawal by 2 and 100Hz EA may provide
useful information for the design of appropriate care for
opiate addicts in drug abstinence.
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